Our Portfolio

export-table

Export table

PRODUCT NAME

THERAPEUTIC AREA

PHARMACEUTICAL
FORM

VISUAL FORM

STRENGTH

REFERENCE
PRODUCT

lactose
free

zone IV

CPP
FEASIBILITY

FILTERS

Therapeutic Area
Select some options
Pharmaceutical Form
Select some options
Zone IV Stability
Select some options
CPP Feasibility
Select some options
Vitamins & Minerals
Soft capsule
20.000 IU (500 μg)
50.000 IU (1250 μg)
100.000 IU (2500 μg)
N/A

II: on-going
IVa: not available
Ivb: not available

No
Respiratory system
Nasal spray solution
(1.0 mg + 50 mg)/ml (10 ml)
(0.5 mg + 50 mg)/ml (10 ml)
Nasic / Cassella-med

II: available
IVa: ext. From b
IVb: available(6)

Yes
Nervous system
Film-coated tablets
25 mg
100 mg
150 mg
200 mg
300 mg
Seroquel / AstraZeneca

II: available
IVa: available
IVb: available

Yes
Nervous system
Film-coated tablets
500 mg
Novalgin / Sanofi Aventis

II: on-going
IVa: not available
IVb: not available

No
Nervous system
Film-coated tablets
10 mg
20 mg
Ebixa / Lundbeck

II: available
IVa: available
IVb: no ext. From a

Yes
Musculoskeletal system
Film-coated tablets
200 mg - 500 mg
Nurofen Ultima / Reckitt Benckiser

II: on-going
IVa: not available
IVb: not available

No
Nervous system
Gastro-resistant hard capsules
120 mg
240 mg
Tecfidera / Biogen Idec

II: on-going
IVa: ext. From b
IVb: on-going

No
Genito-Urinary system & Sex Hormones
Film-coated tablets
2.5 mg
5 mg
10 mg
20 mg
Cialis / Eli Lilly

II: available
IVa: ext. From b
IVb: available

Yes
Dermatologicals
Gel
1 mg/g (20 g)
1 mg/g (30 g)
1 mg/g (50 g)
Fenistil / Novartis

II: available
IVa: available
IVb: no ext. From a

Yes
Cardiovascular System
Tablets
40/5 mg
40/10 mg
80/5 mg
80/10 mg
Twynsta / Boehringer Ingelheim

II: on-going
IVa: ext. From b
IVb: on-going

Yes
Cardiovascular System
Film-coated tablets
5 mg
10 mg
20 mg
40 mg
Crestor / AstraZeneca

II: available
IVa: not available
IVb: not available

Yes
Cardiovascular System
Hard capsules
5 mg + 5 mg
5 mg + 10 mg
10 mg + 5 mg
10 mg + 10 mg
Tritace (Ramipril) / Sanofi & Norvasc (Amlodipine) / Pfizer

II: available
IVa: not available
IVb: not available

Yes
Cardiovascular System
Tablets
12.5 mg
25 mg
50 mg
Esidrex / Novartis

II: available
IVa: not available
IVb: not available

Yes(3)
Cardiovascular System
Film-coated tablets
5 mg + 10 mg
10 mg + 10 mg
10 mg + 20 mg
5 mg + 20 mg
Norvasc (Amlodipine)+Sortis (Atorvastatin) / Pfizer

II: available
IVa: not available
IVb: not available

Yes
Cardiovascular System
Tablets
5 mg
10 mg
20 mg
Xanef (Vasotec, Renitec) / MSD

II: on-going
IVa: not available
Ivb: not available

No
Blood & Blood forming organs
Film-coated tablets
60 mg
90 mg
Brilique / AstraZeneca

II: available
IVa: ext. From b
IVb: available

No
Blood & Blood forming organs
Film-coated tablets
2.5 mg
10 mg
15 mg
20 mg
Xarelto / Bayer

II: on-going
IVa: ext. From b
IVb: on-going

No
Blood & Blood forming organs
Film-coated tablets
2.5 mg
5 mg
Eliquis / Bristol-Myers Squibb

II: on-going
IVa: ext. From b
IVb: on-going

No
Antineoplastic & Immunomodulating Agents
Capsules
2.5 mg
5 mg
7.5 mg
10 mg
15 mg
20 mg
25 mg
Revlimid / Celgene

II: on-going
IVa: ext. From b
IVb: on-going

No
Anti-infectives for systemic use
Film-coated tablets
500 mg
Tavanic / Aventis

N/A

No
Loading more...
* Polpharma Group API CA Dossier suitable for Canadian market
(1) Pending dossier update (new API Valsartan source required)
(2) No CPP feasibility for Hidrozchlorothiazide 50 mg
(3) Dossier availability subject to some restriction
N/A Not Available Data

PRODUCT NAME

THERAPEUTIC AREA

PHARMACEUTICAL
FORM

STRENGTH

REFERENCE
PRODUCT

DOSSIER
AVAILABILITY

FILTERS

Therapeutic Area
Select some options
Pharmaceutical Form
Select some options
Dossier Availability
Select some options
More
Alimentary tract & metabolism
Film-coated tablets
10 mg/5 mg
25 mg/5 mg
Glyxambi/ Boehringer Ingelheim
2024
Alimentary tract & metabolism
Film-coated tablets
5/850 mg
5/1000 mg
Xigduo / Astra Zeneca
2022
Alimentary tract & metabolism
Film-coated tablets
10 mg
25 mg
Jardiance / Boehringer Ingelheim
2022
Alimentary tract & metabolism
Film-coated tablets
5mg/500mg
5mg/850mg
5mg/1000 mg
12.5mg/500mg
12.5mg/850mg
12.5mg/1000mg
Synjardy / Boehringer Ingelheim
2024
Alimentary tract & metabolism
Film-coated tablets
2.5/500 mg
2.5/850 mg
2.5/1000 mg
Jentadueto / Boehringer Ingelheim
2022
Cardiovascular System
Tablets
5 mg
10 mg
Nebilet / Menarini
2022
Cardiovascular System
Film-coated tablets
24mg / 26mg
49mg / 51mg
97mg / 103mg
Entresto / Novartis
2023 (EU) / 2022 (CA)
Respiratory system
Inhalation powder
44 mcg
Seebri Breezhaler / Novartis
2023
Respiratory system
Inhalation powder
85/43 mcg
Ultibro Breezhaler / Novartis
2023
Antineoplastic & Immunomodulating Agents
Film-coated tablets
10 mg
20 mg
30 mg
Otezla / Celgene
2022
Antineoplastic & Immunomodulating Agents
Film-coated tablets
5 mg
10 mg
Xeljanz / Pfizer
Early stage
Antineoplastic & Immunomodulating Agents
Prolonged-release tablet
11 mg
Xeljanz / Pfizer
Early stage
Loading more...
* Polpharma Group API CA Dossier suitable for Canadian market
(1) Pending dossier update (new API Valsartan source required)
(2) No CPP feasibility for Hidrozchlorothiazide 50 mg
(3) Dossier availability subject to some restriction
N/A Not Available Data